Detalhe da pesquisa
1.
15-color highly sensitive flow cytometry assay for post anti-CD19 targeted therapy (anti-CD19-CAR-T and blinatumomab) measurable residual disease assessment in B-lymphoblastic leukemia/lymphoma: Real-world applicability and challenges.
Eur J Haematol
; 112(1): 122-136, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37706583